Co-Authors
This is a "connection" page, showing publications co-authored by RICHARD BOND and BURTON F DICKEY.
Connection Strength
1.129
-
beta-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol. 2010 Jun; 10(3):254-9.
Score: 0.364
-
?2-Adrenoceptor signaling in airway epithelial cells promotes eosinophilic inflammation, mucous metaplasia, and airway contractility. Proc Natl Acad Sci U S A. 2017 10 24; 114(43):E9163-E9171.
Score: 0.152
-
Complementary anti-inflammatory effects of a ?-blocker and a corticosteroid in an asthma model. Naunyn Schmiedebergs Arch Pharmacol. 2012 Feb; 385(2):203-10.
Score: 0.100
-
New perspectives regarding ?(2) -adrenoceptor ligands in the treatment of asthma. Br J Pharmacol. 2011 May; 163(1):18-28.
Score: 0.097
-
Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J. 2010 Oct; 36(4):963-5.
Score: 0.093
-
Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med. 2010 Jan; 16(1):1-5.
Score: 0.089
-
Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A. 2009 Feb 17; 106(7):2435-40.
Score: 0.083
-
Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008 Mar; 38(3):256-62.
Score: 0.077
-
The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008; 21(1):134-41.
Score: 0.075